BPC-157 vs LL-37
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of BPC-157 and LL-37 (also searched as LL-37 vs BPC-157) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
BPC-157 centers on healing, while LL-37 leans toward healing. On indexed research, LL-37 is ahead (BPC-157: 14 studies, Human evidence; LL-37: 32, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •BPC-157 is strongest for healing; LL-37 for healing.
- •Evidence: BPC-157 Human evidence (14 studies) vs LL-37 Human evidence (32).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
BPC-157 vs LL-37: side-by-side
| Metric | BPC-157 | LL-37 |
|---|---|---|
| Class | Healing | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 14 | 32 |
| Research level | Preclinical | Well Studied |
| Strongest effect | Healing & recovery | Healing & recovery |
| Healing & recovery | 4.0▲ | 4.0▲ |
| Muscle & body comp | 3.0▲ | 1.0 |
| Metabolic & appetite | 2.0▲ | 2.0▲ |
| Neuro & mood | 2.0▲ | 1.0 |
| Sleep & circadian | 1.0▲ | 0.0 |
| Inflammation & immune | 4.0▲ | 4.0▲ |
| Skin & aesthetics | 1.0 | 2.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | BPC-157 | LL-37 |
|---|---|---|
| Mechanism | Body-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling | Disrupts microbial membranes, leading to cell lysis |
| Route | Subcutaneous / oral (research use) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is BPC-157?
Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.
Full BPC-157 profile, mechanism & studies →What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a significant role in the innate immune response. It exhibits a range of biological activities, including antimicrobial, immunomodulatory, and wound healing properties. LL-37 is produced by various cells, including epithelial cells and neutrophils, and is known to interact with a variety of pathogens, including bacteria, viruses, and fungi.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~4.0/5 |
| Muscle | BPC-157 | 3.0/5 effect signal |
| Metabolic | Even | Both ~2.0/5 |
| Neuro | BPC-157 | 2.0/5 effect signal |
| Sleep | BPC-157 | 1.0/5 effect signal |
| Inflammation | Even | Both ~4.0/5 |
| Skin | LL-37 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack BPC-157 and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
BPC-157 vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
BPC-157 has 14 approved studies indexed (Human evidence), and LL-37 has 32 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is BPC-157 or LL-37 better?
It depends on your goal. BPC-157 is strongest for healing; LL-37 for healing. LL-37 has more indexed studies (32). See the goal-by-goal breakdown above.
Is BPC-157 or LL-37 better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is BPC-157 or LL-37 better for muscle?
BPC-157 leads on the muscle & body-composition axis (3.0/5).
Which has more research, BPC-157 or LL-37?
BPC-157 has 14 approved studies indexed (Human evidence); LL-37 has 32 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack BPC-157 and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of BPC-157 vs LL-37?
BPC-157: no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is BPC-157 or LL-37 FDA-approved?
BPC-157 is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than BPC-157?
For healing, LL-37 has the edge; for healing, BPC-157 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
BPC-157 and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.